Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 217
Filter
1.
Clin Exp Allergy ; 48(7): 806-813, 2018 07.
Article in English | MEDLINE | ID: mdl-29603800

ABSTRACT

BACKGROUND: The influence of airway remodelling and inflammation in preschoolers with severe recurrent wheeze on asthma outcomes is poorly understood. OBJECTIVE: To assess their association with asthma symptoms and lung function at school age. METHODS: Preschoolers (38.4 months) initially investigated with bronchial biopsies were re-assessed for asthma symptoms and lung function at school age. RESULTS: Thirty-six of 49 preschoolers (73.5%) were assessed at 10.9 years. Twenty-six (72.2%) had persistent asthma. Submucosal eosinophil counts were higher in children with severe exacerbations at school age than in those without (16/0.1 mm2 [11.2-30.4] vs 8/0.1 mm2 [2.4-17.6], P = .02), and correlated with the number of severe exacerbations (P = .04, r = .35). Submucosal neutrophil counts correlated with FEV1/FVC (P < .01, r = .47) and FEF25-75% predicted (P = .02, r = .43). Airway smooth muscle (ASM) area correlated with FEV1/FVC (P < .01, r = .51). Vessel numbers negatively correlated with FEV1% predicted and FEV1/FVC (P = .03, r = -.42; P = .04, r = -.41; respectively) and FEF25-75% predicted (P = .02, r = -.46). CONCLUSION: Eosinophilic inflammation in preschoolers with severe recurrent wheeze might be predictive of future severe exacerbations, neutrophilia might be associated with better lung function. Changes in ASM and vascularity might affect lung function at school age.


Subject(s)
Airway Remodeling , Asthma/epidemiology , Inflammation/epidemiology , Respiratory Sounds , Age Factors , Allergens/immunology , Asthma/complications , Asthma/diagnosis , Asthma/etiology , Biomarkers , Child , Child, Preschool , Female , Humans , Immunoglobulin E/immunology , Infant , Inflammation/etiology , Leukocyte Count , Male , Patient Outcome Assessment , Recurrence , Respiratory Function Tests , Respiratory Sounds/etiology , Severity of Illness Index , Spirometry
2.
Pediatr Allergy Immunol ; 29(1): 84-89, 2018 02.
Article in English | MEDLINE | ID: mdl-29047169

ABSTRACT

BACKGROUND: A minority of children reporting non-immediate reactions to beta-lactams (BLs) are allergic. Allergy workup usually includes late-reading (48-72 hours) skin tests (ST) and short (1-3 days) drug provocation tests (DPT), regardless of the chronology of the index reaction. The sensitivity of hyper-late-reading (≥6-7 days) ST and of prolonged DPT for the diagnosis of non-immediate hypersensitivity to BLs is yet to be determined. OBJECTIVES: To establish the diagnostic values of late-reading ST and hyper-late-reading ST and of prolonged DPT in children reporting non-immediate reactions to BLs. METHODS: Prospective assessment of children reporting non-immediate reactions to BLs with late- and additional hyper-late-reading intradermal (ID) and patch tests, and if negative, with prolonged DPT. RESULTS: Five hundred and fifty children reporting reactions to a single or several BLs (674 suspected BLs) were included. Non-immediate hypersensitivity to BLs was diagnosed in 63 children (11.5%), reporting 66 reactions (9.8%), based on responses in ST (n = 17, 25.8%: 5 to ID, 8 to patch tests, and 4 to both tests), DPT (n = 43, 65.2%), and clinical history (n = 6, 9.1%), including 3/9 children with severe cutaneous adverse reactions. Skin test positivity was observed after the 6-7th day in 14/17 children, and DPT positivity after a median time of 3 days. No severe reaction was observed after ST or during prolonged DPT. CONCLUSION: Additional hyper-late-reading of ST enhanced their positivity. However, their overall sensitivity remained weak, especially in non-severe cases. Prolonged DPT are safe and may improve the performance of DPT in the diagnosis of non-immediate hypersensitivity to BLs.


Subject(s)
Anti-Bacterial Agents/adverse effects , Drug Hypersensitivity/diagnosis , Skin Tests/methods , beta-Lactams/adverse effects , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Prospective Studies , Time Factors
3.
Rev Mal Respir ; 34(2): 134-146, 2017 Feb.
Article in French | MEDLINE | ID: mdl-28262277

ABSTRACT

The spectrum of respiratory viruses is expanding and emerging diseases have been described regularly over the last fifteen years. The origin of these emerging respiratory viruses may be zoonotic (by crossing species barrier, after changes to RNA viruses such as avian influenza virus type A or coronaviruses), or related to the use of new identification techniques (metapneumovirus, bocavirus). The relationship between bronchiolitis and asthma is now better understood thanks to prospective follow up of birth cohorts. The role of rhinovirus has become predominant with respect to respiratory syncytial virus. The identification of predisposing factors immunological, functional, atopic and genetic, for the onset of asthma after rhinovirus infection suggests that viral infection reveals a predisposition rather than itself being a cause of asthma. The role of bacteria in the natural history of asthma is also beginning to be better understood. The results of the COPSAC Danish cohort have shown the frequency of bacterial identification during wheezy episodes before 3 years, and the impact of bacterial colonization at the age of one month on the onset of asthma by age 5 years. The role of bacterial infections in severe asthma in young children is also discussed.


Subject(s)
Microbial Interactions/physiology , Respiratory System/microbiology , Respiratory System/virology , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/virology , Bacterial Infections/complications , Bacterial Infections/virology , Child , Child, Preschool , Humans , Infant , Respiratory Distress Syndrome/microbiology , Respiratory Distress Syndrome/virology , Respiratory Syncytial Viruses/pathogenicity , Respiratory Syncytial Viruses/physiology , Virus Diseases/complications , Virus Diseases/microbiology
4.
J Cyst Fibros ; 15(6): 825-833, 2016 11.
Article in English | MEDLINE | ID: mdl-27289197

ABSTRACT

BACKGROUND: Body composition (BC) analysis based on bioelectrical impedance analysis (BIA) provides conflicting results. The purpose of the study was to validate an equation specific for young patients with cystic fibrosis (CF), describe their BC and investigate its association with lung function. METHODS: Fifty-four young CF patients were evaluated by BIA and dual X-ray absorptiometry (DXA). An empirically derived CF-specific equation for fat-free mass (FFM) estimation by BIA was elaborated after stepwise multivariate regression and the agreement between BIA and DXA was assessed by Bland-Altman plots. The association between BC and lung function was investigated by regression analysis. RESULTS: The mean difference between the BIA and DXA assessment was close to zero. A total of 22.5% of patients (n=9) presented a FFM z-score≤-2. They had a worse pulmonary function and diaphragmatic impairment. Among these 9 patients, 7 had a normal BMI z-score>-1. CONCLUSIONS: BIA, based on a CF-specific equation, is a reliable method for BC assessment and allows the identification of patients at risk of nutritional degradation and bad respiratory prognosis.


Subject(s)
Body Composition , Cystic Fibrosis , Absorptiometry, Photon/methods , Adolescent , Body Mass Index , Child , Cystic Fibrosis/diagnosis , Cystic Fibrosis/physiopathology , Electric Impedance , Female , France , Humans , Male , Prognosis , Prospective Studies , Respiratory Function Tests/methods , Statistics as Topic , Young Adult
7.
Arch Pediatr ; 23(5): 525-31, 2016 May.
Article in French | MEDLINE | ID: mdl-27021883

ABSTRACT

Chronic interstitial lung disease (ILD) in children is a heterogeneous group of rare lung disorders characterized by an inflammatory process of the alveolar wall and the pulmonary interstitium that induces gas exchange disorders. The diagnostic approach to an ILD involves three essential steps: recognizing the ILD, appreciating the impact, and identifying the cause. The spectrum of clinical findings depends to a large extent on age. In the newborn, the beginning is often abrupt (neonatal respiratory distress), whereas there is a more gradual onset in infants (failure to thrive, tachypnea, indrawing of the respiratory muscles). In older children, the onset is insidious and the diagnosis can only be made at an advanced stage of the disease. The diagnosis is based on noninvasive methods (clinical history, respiratory function tests, chest X-ray, and high-resolution CT scan) and invasive techniques (bronchoalveolar lavage, transbronchial biopsy, video-assisted thoracoscopic biopsy, and open lung biopsy). The treatment of interstitial lung disease in children depends on the nature of the underlying pathology. The most common therapeutic approach involves the use of corticosteroids and immunosuppressive agents for their anti-inflammatory and antifibrotic effects. Children with ILD also need support therapy (oxygen therapy, nutritional support, treatment of pulmonary arterial hypertension, vaccination). Lung transplantation is discussed in patients with severe respiratory failure.


Subject(s)
Glucocorticoids/therapeutic use , Immunosuppressive Agents/therapeutic use , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/therapy , Oxygen/therapeutic use , Child , Chronic Disease , Drug Therapy, Combination , Humans , Lung Diseases, Interstitial/classification , Lung Diseases, Interstitial/etiology , Prognosis , Treatment Outcome
8.
EMC Pediatr ; 51(3): 1-15, 2016 Sep.
Article in Spanish | MEDLINE | ID: mdl-32288516
10.
Allergy ; 69(6): 784-90, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24725204

ABSTRACT

BACKGROUND: Guidelines recommend regular assessment of asthma control. The Childhood Asthma Control Test (C-ACT) is a clinically validated tool. AIM: To evaluate asthma control according to GINA2006, NAEPP, pediatrician's assessment (PA), and C-ACT in asthmatic children visiting their ambulatory pediatrician or tertiary care pediatric pulmonologist. METHODS: Demographic data, treatment, and number of severe exacerbations during the previous year were collected. Control was assessed using (i) strict GINA 2006 criteria, (ii) GINA without taking into account the exacerbation item, (iii) NAEPP criteria, and (iv) PA. Children and parents filled out the C-ACT. RESULTS: Five hundred and twenty-five children completed the survey (mean age: 7.7 years; 28% ≤ 6 years). 78% had a controller treatment. 58% reported ≥ 1 severe exacerbation. C-ACT was ≤ 19 in 29.5%. Control was not achieved in 76.5%, 55%, 40%, and 34% according to GINA 2006 guidelines, NAEPP guidelines, GINA 2006 without exacerbation criteria, and PA, respectively. C-ACT was significantly lower in children ≤ 6 years old (P = 0.002) or with severe exacerbations (P < 0.0001). According to PA, 89% of patients with a C-ACT > 21 were controlled and 85% of patients with a C-ACT < 17 not controlled. CONCLUSION: We observed discrepancies between the different tools applied to assess asthma control in children, and the impact of age and exacerbations. Cutoff point of 19 of C-ACT was not associated with the best performance compared to PA. Assessment of control should take into account symptoms and lung function as suggested by the latest GINA guidelines as well as exacerbation over a long period.


Subject(s)
Asthma/prevention & control , Asthma/therapy , Age Factors , Asthma/diagnosis , Child , Child, Preschool , Disease Progression , Female , France , Humans , Male , Outcome Assessment, Health Care , Pediatrics , Practice Guidelines as Topic , Prospective Studies , Severity of Illness Index , Surveys and Questionnaires
11.
Arch Pediatr ; 21(4): 418-23, 2014 Apr.
Article in French | MEDLINE | ID: mdl-24613479

ABSTRACT

Recommendations for the use of diagnostic testing in low respiratory infection in children older than 3 months were produced by the Groupe de Recherche sur les Avancées en Pneumo-Pédiatrie (GRAPP) under the auspices of the French Paediatric Pulmonology and Allergology Society (SP(2)A). The Haute Autorité de santé (HAS) methodology, based on formalized consensus, was used. A first panel of experts analyzed the English and French literature to provide a second panel of experts with recommendations to validate. Only the recommendations are presented here, but the full text is available on the SP(2)A website.


Subject(s)
Diagnostic Tests, Routine , Lung Diseases/diagnosis , Chlamydial Pneumonia/diagnosis , Diagnostic Tests, Routine/methods , Evidence-Based Medicine , France , Humans , Infant , Lung Diseases/therapy , Pneumonia, Bacterial/diagnosis , Pneumonia, Mycoplasma/diagnosis , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Viral/diagnosis , Pulmonary Aspergillosis/diagnosis
15.
Rev Mal Respir ; 30(2): 115-24, 2013 Feb.
Article in French | MEDLINE | ID: mdl-23419442

ABSTRACT

According to the Global Initiative for Asthma (GINA) classification, mild asthma includes intermittent and mild persistent asthma. It represents more than 75% of asthmatic children. The symptoms and functional impact are well described. Mild asthma can lead to severe exacerbations. Progression to more severe disease may occur. Consequently, it is important to diagnose mild asthma, to initiate the appropriate treatment early, and to identify the risk factors for aggravation. Nevertheless, mild asthma is under-diagnosed and under-treated. Bronchial inflammation and remodeling are observed in mild asthma. A daily low-dose of inhaled corticosteroids is the reference treatment for mild persistent asthma. Intermittent inhaled corticosteroids cannot be recommended in children with mild persistent asthma.


Subject(s)
Asthma/epidemiology , Adolescent , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Adult , Age of Onset , Airway Remodeling , Anti-Asthmatic Agents/adverse effects , Anti-Asthmatic Agents/therapeutic use , Asthma/diagnosis , Asthma/drug therapy , Asthma/physiopathology , Bronchitis/complications , Bronchitis/physiopathology , Child , Child, Preschool , Cohort Studies , Comorbidity , Contraindications , Disease Progression , Environmental Exposure , Female , Humans , Infant , Leukotriene Antagonists/therapeutic use , Male , Middle Aged , Obesity/epidemiology , Phenotype , Risk Factors , Sex Distribution , Symptom Assessment
16.
Rev Mal Respir ; 30(2): 152-60, 2013 Feb.
Article in French | MEDLINE | ID: mdl-23419446

ABSTRACT

Post-infectious bronchiolitis obliterans (BO) is characterized by inflammatory and fibrotic lesions of small airways following a pulmonary infection and leading to some degree of airway obstruction. It represents a rare cause of chronic obstructive pulmonary disease, and is probably underestimated, especially when the lesions affect small areas of the lungs. The clinical features differ between children and adults. In children, adenovirus is the most frequently involved infectious agent, especially the more virulent serotypes 3, 7 and 21. The clinical and radiological signs vary widely and the functional outcome depends on the extent of the lung injury. The diagnosis is based on the medical history, the CT-scan and functional data. The treatment is symptomatic. The most severe forms may result in chronic respiratory insufficiency. In adults, the frequency of obstructive injuries of the small airways in the context of lung infection is unclear. Parenchymal lesions are often present, resulting in BO with organizing pneumonia. These lesions alter the clinical presentation and the radiographic features of the initial infectious disease and often prove difficult to diagnose and manage. Several authors have published clinical cases describing presumed efficacy of systemic corticosteroids but the data are scarce.


Subject(s)
Bronchiolitis Obliterans/etiology , Respiratory Tract Infections/complications , Adrenal Cortex Hormones/therapeutic use , Adult , Anti-Bacterial Agents/therapeutic use , Biopsy , Bronchiolitis Obliterans/diagnosis , Bronchiolitis Obliterans/epidemiology , Bronchiolitis Obliterans/physiopathology , Bronchiolitis Obliterans/prevention & control , Bronchiolitis Obliterans/therapy , Bronchodilator Agents/therapeutic use , Child , Cryptogenic Organizing Pneumonia/diagnosis , Cryptogenic Organizing Pneumonia/drug therapy , Cryptogenic Organizing Pneumonia/etiology , Cryptogenic Organizing Pneumonia/pathology , Diagnostic Imaging/methods , Humans , Lung/pathology , Lung Transplantation , Oxygen Inhalation Therapy , Pneumonectomy/methods , Prognosis , Pulmonary Atelectasis/etiology , Pulmonary Atelectasis/surgery , Pulmonary Disease, Chronic Obstructive/etiology , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/virology , Risk Factors , Vaccination
17.
Allergy ; 67(8): 976-97, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22702533

ABSTRACT

Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.


Subject(s)
Asthma/diagnosis , Asthma/therapy , Adolescent , Asthma/classification , Asthma/prevention & control , Child , Child, Preschool , Humans , Infant , Infant, Newborn
18.
Rev Mal Respir ; 29(4): 601-11, 2012 Apr.
Article in French | MEDLINE | ID: mdl-22542416

ABSTRACT

INTRODUCTION: Congenital lung lesions comprise a broad spectrum of various malformations including congenital cystic adenomatoid malformation (CCAM), bronchopulmonary sequestration (BPS), congenital lobar emphysema, bronchial atresia and bronchogenic cyst. This review aims at the description of their natural history, and of the underlying pathophysiological mechanisms. STATE OF THE ART: Congenital lung lesions are frequently diagnosed antenatally and many remain asymptomatic after birth. In the absence of antenatal identification, they are usually revealed by the occurrence of infection. In some cases, spontaneous resolution of the malformation can occur. Different pathogenic hypotheses are discussed for the origin of these abnormalities, and common processes appear likely to all of these malformations. Factors involved in the process of branching seem to play a particularly important role. PERSPECTIVES: Prospective follow-up of operated and unoperated children would complete our knowledge about the natural history of these lesions. The contribution of experimental models has led to advances in the understanding of pathogenic mechanisms. Further studies are needed to identify the factors initiating the malformative process.


Subject(s)
Lung Diseases/congenital , Lung/abnormalities , Respiratory System Abnormalities/etiology , Bronchopulmonary Sequestration/diagnosis , Bronchopulmonary Sequestration/etiology , Bronchopulmonary Sequestration/genetics , Bronchopulmonary Sequestration/therapy , Cystic Adenomatoid Malformation of Lung, Congenital/diagnosis , Cystic Adenomatoid Malformation of Lung, Congenital/etiology , Cystic Adenomatoid Malformation of Lung, Congenital/genetics , Cystic Adenomatoid Malformation of Lung, Congenital/therapy , Disease Progression , Humans , Lung Diseases/complications , Lung Diseases/genetics , Lung Diseases/pathology , Models, Biological , Respiratory System Abnormalities/complications , Respiratory System Abnormalities/genetics , Respiratory System Abnormalities/pathology
19.
Arch Pediatr ; 19(3): 330-4, 2012 Mar.
Article in French | MEDLINE | ID: mdl-22306361

ABSTRACT

Allergic rhinitis (AR) is a common IgE dependent disorder. AR is maybe one of the steps of the allergic march, which starts with atopic dermatitis and food allergy and includes atopic asthma. AR and asthma are frequently associated. AR is frequently under-diagnosed and undertreated although it affects quality of life and school performance. Management of AR depends on its severity and will associate environmental control (best guided by environmental investigation and skin testing of specific IgE antibodies), pharmacotherapy (with antihistamines and intranasal corticosteroids as first line drugs). At present allergen immunotherapy is considered in patients with severe AR, insufficiently controlled by pharmacotherapy and who demonstrate specific IgE antibodies to relevant allergens. Sublingual immunotherapy is well tolerated. Only immunotherapy with the right allergens has the potential to alter the natural history of the allergic march, by preventing the development of new allergen sensitizations and reducing the risk for the subsequent development of asthma. This fact might extend the indications of specific allergen immunotherapy. Patients (and parents) education is of utmost importance in the management of allergic disorders.


Subject(s)
Anti-Allergic Agents/therapeutic use , Asthma/therapy , Desensitization, Immunologic/methods , Rhinitis, Allergic, Perennial/therapy , Rhinitis, Allergic, Seasonal/therapy , Administration, Sublingual , Allergens/administration & dosage , Allergens/immunology , Asthma/diagnosis , Child , Comorbidity , Epitopes/immunology , Humans , Immunoglobulin E/blood , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Seasonal/diagnosis , Treatment Outcome
20.
Arch Pediatr ; 18 Suppl 1: S15-21, 2011 May.
Article in French | MEDLINE | ID: mdl-21596282

ABSTRACT

Fungal colonization in cystic fibrosis patient is frequent and dominated by Aspergillus fumigatus (A. fumigatus). Mycological analysis on specific media showed other filamentous species Scedosporium, Geosmithia argillacea. Prospective studies are necessary to appreciate prevalence and pathogenicity in this pathology. A. fumigatus causes the most frequently allergic bronchopulmonary aspergillosis (ABPA). Invasive infection is exceptional in this context. An early diagnosis is important to avoid bronchial deterioration but is very difficult despite international consensus. New more specific biological markers are evaluated. Oral corticotherapy is the cornerstone of therapy but adverse effects are more frequent in cystic fibrosis. Antifungal therapy has a corticosteroid-sparing effect. New therapeutic strategies have to be evaluated.


Subject(s)
Cystic Fibrosis/complications , Mycoses/etiology , Administration, Oral , Antifungal Agents/therapeutic use , Aspergillus fumigatus/isolation & purification , Cystic Fibrosis/diagnosis , Cystic Fibrosis/drug therapy , Early Diagnosis , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Mycoses/diagnosis , Mycoses/drug therapy , Mycoses/microbiology , Pulmonary Aspergillosis/microbiology , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...